Endostatin in disease modulation: From cancer to beyond
Vascular Pharmacology · 2025-03 · 158 · 107459
DOI: 10.1016/j.vph.2024.107459 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Vascular Pharmacology, 2025-03. Verfasst von J Anakha und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar, Mohali 160062, Punjab, Ind…. Hauptthemen laut MEDLINE: Endostatins, Neoplasms, Angiogenesis Inhibitors. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 158 Literaturangaben. Gefördert von: Council of Scientific & Industrial Research.
Abstract (Originalsprache)
Angiogenesis plays a pivotal role in various pathological conditions, making it a key target in therapeutic development. Anti-angiogenic therapies are gaining traction for their potential in treating a range of angiogenesis-dependent diseases. Among these, endogenous angiogenesis inhibitors, particularly endostatin, have garnered significant attention for their therapeutic potential. While extensively studied for its anti-angiogenic effects in cancer, endostatin also exhibits anti-atherosclerotic and anti-fibrotic properties, broadening its therapeutic scope. Despite the successful clinical use of recombinant human endostatin in China for nearly two decades, its broader therapeutic potential remains underexplored. Thus, this review delves into the multifaceted applications of endostatin, examining its role in ocular diseases, inflammation, reproductive disorders, and tumor angiogenesis. Furthermore, it provides a comprehensive overview of its emerging roles beyond angiogenesis, particularly in the context of atherosclerosis and fibroproliferative conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar, Mohali 160062, Punjab, India. Electronic address: btp21_anakha@niper.ac.in.
- Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar, Mohali 160062, Punjab, India.
- Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar, Mohali 160062, Punjab, India. Electronic address: apande@niper.ac.in.
Förderung
- Council of Scientific & Industrial Research
Zitieren
APA
Anakha, J., Prasad, Y. R., & Pande, A. H. (2025). Endostatin in disease modulation: From cancer to beyond. Vascular Pharmacology, 158, 107459. https://doi.org/10.1016/j.vph.2024.107459
Vancouver
Anakha J, Prasad YR, Pande AH. Endostatin in disease modulation: From cancer to beyond. Vascular Pharmacology. 2025;158:107459. doi:10.1016/j.vph.2024.107459
BibTeX
@article{Anakha2025,
author = {Anakha, J and Prasad, Yenisetti Rajendra and Pande, Abhay H},
title = {Endostatin in disease modulation: From cancer to beyond},
journal = {Vascular Pharmacology},
year = {2025},
volume = {158},
pages = {107459},
doi = {10.1016/j.vph.2024.107459}
}
EUVIMED